This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acura Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Acura Pharmaceuticals (ACUR)

Q2 2012 Earnings Call

July 31, 2012 8:30 am ET

Executives

David Carey

Robert B. Jones - Chief Executive Officer, President and Director

Peter A. Clemens - Chief Financial Officer, Principal Accounting officer, Senior Vice President of Investor Relations and Secretary

Analysts

Michael Kallai Tong - Wells Fargo Securities, LLC, Research Division

Kevin Kedra - Gabelli & Company, Inc.

James Liberman

Robert Cummins Hazlett - Roth Capital Partners, LLC, Research Division

Tom Marks

Presentation

Operator

Good day, everyone, and welcome, ladies and gentlemen, to the Acura Pharmaceutical's Conference Call. As a reminder, today's call is being recorded. [Operator Instructions] At this time, I'd like to turn the call over to David Carey of Lazar Partners. Please go ahead, sir.

David Carey

Thank you. Before we begin, I'd like to remind you that any discussion that takes place during this conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current view of future events and operations including, but not limited to, statements pertaining to the company's expectations regarding OXECTA and other products licensed to Pfizer, the company's product development pipeline, commercial plans for the NEXAFED product, the commercial potential of the company's products and plans to maximize this potential, future product sales and financial results and the company's strategy for long-term growth. Forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Certain factors that may cause actual results to differ materially from the forward-looking statements are discussed in the company's press release issued yesterday evening and the Risk Factors section and other sections of the company's Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs